A 42-year-old Japanese male was admitted to our hospital because of congestive heart failure (CHF). A diagnosis of primary amyloidosis was made on the basis of a heavy deposition of amyloid in the gastric submucosal tissue in addition to the hematological and immunological findings. Intermittent chemotherapy in combination with daily oral dimethylsulfoxide (DMSO) resulted in a dramatic decrease of plasma cells in the marrow as well as a gradual improvement of CHF. With this therapy, the cardiac ejection fraction was markedly improved. This case indicates that the long-standing administration of DMSO combined with cytoreductive chemo therapy is therefore effective in treating some cases with primary amyloidosis. (Internal Medicine 31: 544-548, 1992) 
Introduction
Amyloidosis is characterized by a deposition of in soluble amyloid proteins in various organs, and thus clinical manifestations are usually the result of the im pairment of various functions of these organs. Immuno logical and molecular studies have revealed different origins of amyloid proteins in different types of amy loidosis (1) (2) (3) (4) . One type of familial amyloidosis is known to be caused by the deposition of mutated transthyretin in nerve tissues. In primary amyloidosis and myeloma associated amyloidosis, the amyloid protein deposited in the parenchymal tissues is identical to the fragments containing the variable region of the circulating mono clonal immunoglobulin (Ig) light chain (5, 6) , with a predominance of that of lambda type, by immunohisto chemical analysis (7) .
For the purpose of dissolving deposited amyloid protein, dimethylsulfoxide (DMSO) has been used pre ferentially, and has provided a limited improvement of clinical symptoms (8) . In addition, chemotherapy with an alkylating agent has been reported to produce an improvement of clinical symptoms, with long-term sur vival in some cases (9) . In the present report, we describe a case of primary amyloidosis in which a dramatic improvement of heart failure and hepatomegaly was obtained after the prolonged oral administration of DMSO in combination with intermittent cytoreductive chemotherapy consisting of melphalan and prednisone.
Case Report
The patient, a 42-year-old Japanese male, had been well until September 1987, when he developed arrythmia and exertional dyspnea. At the end of December 1987, he noticed peripheral and facial edema. In May 1988, he was admitted to one of our affiliated hospitals be cause of nocturnal dyspnea and abdominal distention and was then referred to us under a diagnosis of con gestive heart failure (CHF) due to hypertrophic car diomyopathy. His body weight was 62.7kg and height 163.5 cm. The physical examination revealed bilateral pleural effusion and ascites; the liver was palpable 5 finger breadths below the right costal margin. Urinalysis demonstrated proteinuria and Bence-Jones protein.
Peripheral blood counts included hemoglobin 14.0g/dl, RBC 509x l04/mm3, Hct 46.1%, pit 18.1 x 104/mm3, WBC 7.29xlO3/mm3 with 54% polymorphs, 32% lymphocytes, 9% monocytes, 4% eosinophils and 1% basophils. The laboratory data on admission are sum marized in Table 1 . The bone marrow was normocellular with an increase of cytoplasm-rich plasma cells of up to 23.6% (Fig. 1) marrow cells showed that plasma cells were positive for lambda, but negative for kappa, gamma, mu and delta immunoglobulin heavy chains. Electrophoresis of heavy amyloid in the lamina propria mucosae by Congo red staining (Fig. 4a) . For treatment of the CHF, an oral administration of 160mg of furosemide, 50mg of spironolactone, 0.25 mg of digoxin and 37.5mg of captopril were instituted. A gradual decrease of ascites and pleural effusion was noted thereafter. A diagnosis of primary amyloidosis was made on the basis of the bone marrow picture, the presence of monoclonal light chain in the serum and urine, and biopsy findings of the gastric mucosa. Chemotherapy with intermittent melphalan (12mg x 4 days) and prednisone (40 mg x 4 days) (MP therapy) was started on October 8, 1988 . For the purpose of dissolving deposited amyloid protein, dimethylsulfoxide (DMSO) was started on October 27 at a starting dose of 4ml/day. On December 3, 1988, the patient developed Adams Stokes syndrome because of a prolonged atrioventricular block, which was confirmed by ECG. In order to prevent further arrhythmic complications, a pacemaker was implanted. At this point, he presented with slight right heart failure; a cervical vein was visible 5 cm above the sternal angle and both hepatojugular reflex and pleural effusion were present. On December 16, 1988 , a per manent pacemaker (NeosM-VSBP) was implanted into the right ventricle at a basic rate of 50bpm. After the implantation of the pacemaker, he never again developed Adams-Stokes syndrome and was discharged on a pre scription of 37.5 mg of captopril, 360mg of azosemide, 1.5mg of warfarin and 8ml of DMSO. Since discharge, he has been doing well and is in complete remission (CR) without any increase of plasma cells in the bone marrow under MP therapy every 6-8 weeks plus oral DMSO (8ml/day) for more than 28 months. A dramatic decrease of liver size was demonstrated as a result of this therapy (Fig. 5) , and a chest roentgenogram revealed the disappearance of pleural effusion. On February 6, 1991, cardiac function was evaluated by UCG. As shown in Fig. 3b and Table 2 , the movement of the cardiac walls was markedly improved and the wall thickness was reduced. Atrial fibrillation, however, did not revert to its normal sinus rhythm. A biopsy of the gastric and duodenal mucosa on March 4, 1991, showed complete disappearance of amyloid protein (Fig. 4b) . Discussion
Amyloidosis encompasses various heterogeneous clinical entities, and the clinical manifestations are known to be produced by a disturbance of the functions of the involved organs. Thus, an inhibition of the production of amyloid precursors and a dissolution of the deposited amyloid protein would be expected to alleviate the impaired organ functions. Among a variety of amy loidoses, amyloid light chain (AL) deposition disease is provoked by the production of monoclonal undissolved AL protein by plasma cells in primary amyloidosis, or by myeloma cells in multiple myeloma. In the present case, the increased atypical plasma cells in the bone marrow were probably the source of the AL protein, since the immunohistochemical staining of the bone marrow cells demonstrated the presence of a monoclonal lambda light chain protein in the cytoplasm, and the same type of protein was present in both the urine and plasma. In the present patient, the amount of Bence-Jones protein in the urine was less than 1g/day and it disap peared after only two courses of chemotherapy. Although plasma cells in the marrow initially increased in number, morphological abnormalities were not so obvious ( Fig. 1) and aggregates of plasma cells were not prominent before the treatment. The lack of bone lesions, renal dysfunc tion or other symptoms associated with the infiltration of myeloma cells was inconsistent with overt multiple myeloma. Thus, a diagnosis of primary amyloidosis rather than multiple myeloma was made in this case. Our strategy for the treatment of the disease was to dissolve the insoluble AL protein deposits by the daily administration of a small amount of DMSO and to reduce the production of immunoglobulin by cytoreductive chemotherapy. Twenty-eight months after the initiation of the therapy, no AL protein was demonstrated in biopsy specimens of the gastric and duodenal mucosa (Fig. 4b) . In addition, the decrease in the thickness of the cardiac walls probably reflected a decrease of amyloid deposition in the myocardium. Thus, the effect of the therapy chosen for the present case of amyloidosis was obvious.
The effect of colchicine in preventing acute attacks and further deposition of amyloid has previously been reported in patients with familial Mediterranean fever (10) . However, a randomized study of colchicine com pared with cytoreductive therapy (MP therapy) for patients with amyloidosis complicating cardiac failure confirmed a significantly better survival in the subgroup of patients treated with MP (ll) . Recently, Gertz and Kyle reported a prolonged survival in 18% of 153 patients with primary systemic amyloidosis and emphasized the importance of MP therapy (9) .
The effects of DMSO on amyloid was first reported by Isobe and Osserman in 1976 (12) . Since then, the improvement of renal functions in amyloid A (AA) amyloidosis has also been reported (13, 14) with DMSO therapy. However, DMSO frequently causes various adverse effects such as skin rash or diarrhea, which are sometimes intolerable. In this patient, no obvious adverse effects were observed, and a daily oral administration of 8ml of DMSO was continued for more than 32 months. These results indicate that the long-term daily adminis tration of a tolerable dose of DMSO may dissolve AL protein, and that it is useful for clinical application. In addition, our combination chemotherapy was also effective in the present patient, since a marked decrease of plasma cells in the bone marrow from 23.6% to 4.4% was achieved within two months. This therapy may thus have prevented the further deposition of AL protein in various organs. Histologic regression was confirmed in only one case with primary hepatic amyloidosis after treatment with MP (15) and in one with AA amyloidosis with DMSO and prednisolone (16) . Thus, this is the first case treated with MP and DMSO in which regression of AL amyloidosis was confirmed by a duodenal biopsy. Kyle and Greip reported that the primary cause of death in patients with primary amyloidosis was cardiac complications (40%) followed by renal failure (10%) (17) , and that the median survival of patients with CHF from the onset of symptoms to death was only six months (18) . Thus, the present therapy was obviously effective. Recent reports have also indicated that the addition of alpha-interferon to chemotherapy dramatically im proves the survival of patients with multiple myeloma (19, 20) . Although an increased rate of acute leukemia in patients with multiple myeloma undergoing MP therapy has been reported (21), the long-term administration of DMSO, chemotherapy with an alkylating agent and alpha-interferon may be worth employing in a future study.
